SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 217.65

Change

-1.25 (-0.57)%

Market Cap

N/A

Volume

41.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.14 (+0.52%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.17 (+0.33%)

USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.56 (+0.27%)

USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.21 (+0.38%)

USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.36 (+2.42%)

USD 54.47B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.33 (+0.31%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

+0.04 (+0.56%)

USD 40.89B
0ZC:F Zscaler Inc

-3.02 (-1.67%)

USD 37.92B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.58% 51% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.58% 51% F 59% D-
Trailing 12 Months  
Capital Gain 11.40% 43% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.40% 43% F 54% F
Trailing 5 Years  
Capital Gain 44.31% 70% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.31% 70% C- 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 8.76% 68% D+ 65% D
Dividend Return 8.76% 66% D+ 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.48% 72% C 92% A
Risk Adjusted Return 103.34% 97% N/A 96% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike